ReviewCurrent drug targets2025
Quorum Sensing and its Inhibition in
Review in Current drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Integrative genomics and structural bioinformatics uncovers AMR-associated drug targets and pqsH inhibitors in multidrug-resistant Pseudomonas aeruginosa JJPA01.Molecular diversity · 2026Article
- Quorum-quenching for bacterial pathogen control and health management in aquaculture: mechanisms, applications, current status and future prospects.Frontiers in systems biology · 2026Review
- Biofilms Exposed: Innovative Imaging and Therapeutic Platforms for Persistent Infections.Antibiotics (Basel, Switzerland) · 2025Review
- Scopoletin and Scoparone fromInfection and drug resistance · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biofilms are complicated microbial communities attached to surfaces, bringing about serious clinical, industrial, and environmental issues due to their resistance to conventional antimicrobial treatments. One critical factor of biofilm formation and persistence is quorum sensing - a mechanism that enables cell-to-cell communication and controls the gene expression pattern depending on the population density. It is based on the constant production, secretion, and response of small signalling molecules, termed auto-inducers. The main role of QS is the regulation of vital processes in the cell, such as biofilm formation and virulence factor production, which intensify pathogenicity, drug resistance, and toxin production. In this respect, interruption of QS can be a potential druggable target, and the discovery of QS-inhibiting agents as anti-virulence compounds may offer an alternative therapeutic approach to conventional antibiotics. Quorum sensing inhibition implies a novel strategy against microbial pathogenicity as it only reduces cell-to-cell communication pathways and thus attenuates various physiological responses coordinated by the QS mechanism. Hence, it qualifies as a suitable target for drug discovery. This article provides a comprehensive overview of the Las, Rhl, Pqs, and Iqs quorum sensing cascades in Pseudomonas aeruginosa, elucidating their molecular targets and regulatory roles in virulence. Focusing on therapeutic potential, the review highlights recently identified QS inhibitors and their mechanisms of action, focusing on molecular targets within QS cascades. The review underscores the critical importance of identifying key molecular targets within QS cascades, as their precise knowledge enables the strategic design of inhibitors that disrupt bacterial communication. This work advances innovative therapeutic paradigms by identifying key QS targets, offering promising strategies to disrupt virulence pathways and combat P. aeruginosa infections.
Indexed as
Identifiers
40248926What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.